Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1995-09-28
1998-02-24
Datlow, Philip I.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
540560, A61K 3155, C07D49514
Patent
active
057212317
ABSTRACT:
N-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno (2-methoxyphenyl)urea, optical isomers thereof and pharmaceutically acceptable salts thereof. The compounds of the present invention strongly and selectively inhibit the expression of VCAM-1 and have an inhibitory effect on leukocyte adhesion to vascular endothelial cells. Accordingly, the compounds of the present invention can be used as cell adhesion inhibitors for prophylaxis or treatment of various diseases in which cell adhesion is involved in the onset and progress thereof.
REFERENCES:
patent: 4992437 (1991-02-01), Naka et al.
patent: 5439905 (1995-08-01), Naka et al.
Derwent Abstract of EP 0 387 613 A1, WPI Acc. No. 90-276391/37.
Harrison's Principles of Internal Medicine, 13th ed. (1994), vol. 2, pp. 1826-1829, Isselbacher et al.
Cecil Textbook of Medicine, 19th ed (1992) Wyngaarden et al, pp. 1049-1053.
Amano Mariko
Ehara Syuji
Kitani Hiroyuki
Komatsu Hirotsugu
Moriwaki Minoru
Datlow Philip I.
Yoshitomi Pharmaceutical Industries Ltd.
LandOfFree
Thienotriazolodiazepine compound and pharmaceutical use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thienotriazolodiazepine compound and pharmaceutical use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thienotriazolodiazepine compound and pharmaceutical use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1875320